Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC2017 | TTP 22 |
| High affinity, ATP-competitive casein kinase 2 (CK2) inhibitor (IC50 = 0.1 μM, Ki = 40 nM). Displays selectivity for CK2 over JNK3, ROCK1 and MET (no inhibitory effects at 10 μM). | |
| BCC2069 | Zardaverine |
| Phosphodiesterase inhibitor, selective for PDE3 and 4 (IC50 values are 0.5 and 0.8 μM respectively). Also available as part of the Phosphodiesterase Inhibitor. | |
| BCC2072 | Ziprasidone hydrochloride monohydrate |
| Atypical antipsychotic that displays combined serotonin and dopamine receptor antagonism. Displays high affinity at 5-HT2A receptors with a 5-HT2A/D2 affinity ratio greater than any other clinically available atypical antipsychotics (pKi values are 9.38, 8.88, 8.69, 8.47, 8.32, 8.14, 7.98, 7.49, 7.33 and 6.28 for 5-HT2A, 5-HT2C, 5-HT1D, 5-HT1A, D2, D3, α1, D4, H1 and D1 receptors respectively). | |
| BCC2080 | A-769662 |
| Potent, reversible AMP-activated protein kinase (AMPK) activator (EC50 = 0.8 μM) that displays selectivity towards β1 subunit-containing heterotrimers. Inhibits fatty acid synthesis (IC50 = 3.2 μM) and decreases plasma glucose and triglyceride levels in vivo. Also inhibits proliferation of mesenchymal stem cells, and impedes reprogramming of mouse embryonic fibroblasts to iPSCs. | |
| BCC2084 | PF-03716556 |
| H+,K+-ATPase inhibitor (pIC50 = 6 in human recombinant ion-leaky assays); more potent in acidic conditions. Highly selective for H+,K+-ATPase in vitro; displays no activity at Na+,K+-ATPase. Also displays selectivity for H+,K+-ATPase over a range of 50 receptors and ion channels (IC50 > 10 μM). Inhibits gastric acid secretion in rat and dog models. | |
| BCC2086 | IU1 |
| Selective inhibitor of Usp14; inhibits the catalytic activity of proteasome-associated Usp14 in vitro (IC50 < 4 μM). Stimulates proteasome activity and substrate degradation. | |
| BCC2087 | LDN 57444 |
| Inhibitor of ubiquitin C-terminal hydrolase-L1 (UCH-L1) activity (Ki = 0.4 μM). Causes cell death through the apoptosis pathway; increases levels of highly ubiquitinated proteins and decreases ubiquitin proteasome activity. Activity leads to dramatic alterations in synaptic protein distribution and spine morphology in vivo. | |
| BCC2088 | NSC 632839 hydrochloride |
| Inhibitor of ubiquitin isopeptidase activity that displays no effect on the proteolytic activity of the proteasome. Induces apoptosis via a Bcl-2-dependent and apoptosome-independent pathway of caspase activation (IC50 values are 15.65 and 16.23 μM in E1A and E1A/C9CN cells respectively). | |
